Repositioning Trimebutine Maleate as a Cancer Treatment Targeting Ovarian Cancer Stem Cells

The overall five-year survival rate for late-stage patients of ovarian cancer is below 29% due to disease recurrence and drug resistance. Cancer stem cells (CSCs) are known as a major contributor to drug resistance and recurrence. Accordingly, therapies targeting ovarian CSCs are needed to overcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Heejin, Kwon, Oh-Bin, Lee, Jae-Eon, Jeon, Yong-Hyun, Lee, Dong-Seok, Min, Sang-Hyun, Kim, Jun-Woo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072797/
https://www.ncbi.nlm.nih.gov/pubmed/33923707
http://dx.doi.org/10.3390/cells10040918

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8072797/
https://www.ncbi.nlm.nih.gov/pubmed/33923707
http://dx.doi.org/10.3390/cells10040918

Ejemplares similares